Trial NCT01826448

View at ClinicalTrials.gov 
Org. Study IDs: PLX108-09

Last trial update was posted on 2020-05-28

MeSH Interventions

Vemurafenib

MeSH Conditions

Melanoma

Other Conditions

Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor V600-mutated BRAF Metastatic Melanoma V600-mutated BRAF Unresectable Melanoma

Stopping Reasons

No activity was observed. BRAFi-naïve participants should have received triple combination treatment (including MEK inhibitor). Continuation was not justified.

Limitations And Caveats

This study was terminated due to business decision before the planned sample size was reached; therefore, the planned outcome measure cannot be evaluated.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID